BSE Code: | NSE Code: | ISIN: | Sector:
Research Report Detail
|Report Date||Call||Price@Call||Target Price
|Current Status||Time Horizon|
|Bank of America Merrill Lynch
|Target Hit|| Long (1Y)
Bank of America Merrill Lynch maintains buy on Aurobindo Pharma
Raising FY15 and FY16 earnings per share estimates by 5 per cent and 4 per cent. US sales hit an all-time high of $187 million in the June quarter. Improving profitability will continue to drive re-rating. Expect margins to remain at 23-24 per cent levels.